Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Carbone

Showing results (201-210 of 283) with videos related to

Pageof 29
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 1, 2012
Added value of a serum proteomic signature in the diagnostic evaluation of lung nodulesChad V Pecot, Ming Li, Xueqiong J Zhang, et al.
Science Translational Medicine|January 10, 2020
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-βAlessandra Metelli, Bill X Wu, Brian Riesenberg, et al.
The Lancet. Oncology|November 10, 2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trialJoel W Neal, Suzanne E Dahlberg, Heather A Wakelee, et al.
Cancer Research|January 25, 2005
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancerJoseph Amann, Shailaja Kalyankrishna, Pierre P Massion, et al.
Nature Immunology|October 20, 2022
SUSD2 suppresses CD8<sup>+</sup> T cell antitumor immunity by targeting IL-2 receptor signalingBao Zhao, Weipeng Gong, Anjun Ma, et al.
Clinical Lung Cancer|August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.
Journal of the National Cancer Institute|November 19, 2015
PDL1 Regulation by p53 via miR-34Maria Angelica Cortez, Cristina Ivan, David Valdecanas, et al.
JTO Clinical and Research Reports|September 30, 2021
Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research AutopsyHui-Zi Chen, Russell Bonneville, Anoosha Paruchuri, et al.
Journal of Extracellular Vesicles|September 12, 2022
An immunogold single extracellular vesicular RNA and protein (<sup>Au</sup> SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patientsLuong T H Nguyen, Jingjing Zhang, Xilal Y Rima, et al.
Pageof 29

Showing results (201-210 of 283) with videos related to

Sort By:
Pageof 29
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 1, 2012
Added value of a serum proteomic signature in the diagnostic evaluation of lung nodulesChad V Pecot, Ming Li, Xueqiong J Zhang, et al.
Science Translational Medicine|January 10, 2020
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-βAlessandra Metelli, Bill X Wu, Brian Riesenberg, et al.
The Lancet. Oncology|November 10, 2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trialJoel W Neal, Suzanne E Dahlberg, Heather A Wakelee, et al.
Cancer Research|January 25, 2005
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancerJoseph Amann, Shailaja Kalyankrishna, Pierre P Massion, et al.
Nature Immunology|October 20, 2022
SUSD2 suppresses CD8<sup>+</sup> T cell antitumor immunity by targeting IL-2 receptor signalingBao Zhao, Weipeng Gong, Anjun Ma, et al.
Clinical Lung Cancer|August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.
Journal of the National Cancer Institute|November 19, 2015
PDL1 Regulation by p53 via miR-34Maria Angelica Cortez, Cristina Ivan, David Valdecanas, et al.
JTO Clinical and Research Reports|September 30, 2021
Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research AutopsyHui-Zi Chen, Russell Bonneville, Anoosha Paruchuri, et al.
Journal of Extracellular Vesicles|September 12, 2022
An immunogold single extracellular vesicular RNA and protein (<sup>Au</sup> SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patientsLuong T H Nguyen, Jingjing Zhang, Xilal Y Rima, et al.
Pageof 29